Medical Care

Global Viral Vector CDMO Market Research Report 2025

The global market for Viral Vector CDMO was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Viral Vector CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Viral Vector CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Viral Vector CDMO in Biopharmaceutical Company is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Viral Vector CDMO include Thermo Fisher Scientific, GenScript ProBio, Hillgene, Charles River Laboratories, Ubrigene, Obio Technology (shanghai), Genesail Biotech (Shanghai), WuXi ATU, Porton Advanced Solutions, Pharmaron, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral Vector CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector CDMO.
The Viral Vector CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vector CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Thermo Fisher Scientific
GenScript ProBio
Hillgene
Charles River Laboratories
Ubrigene
Obio Technology (shanghai)
Genesail Biotech (Shanghai)
WuXi ATU
Porton Advanced Solutions
Pharmaron
Asymchem Laboratories (Tianjin)
Merck
VectorBuilder
Yposkesi
Flash Therapeutics
VIVEBiotech
Miltenyi Bioindustry
Genezen
Miltenyi Biotec
Exthera
Catalent
Segment by Type
IIT Grade
IND Grade
Clinical Trial Grade
Commercial Production Grade
Segment by Application
Biopharmaceutical Company
Academic Scientific Research Institution
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vector CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 IIT Grade
1.2.3 IND Grade
1.2.4 Clinical Trial Grade
1.2.5 Commercial Production Grade
1.3 Market by Application
1.3.1 Global Viral Vector CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Biopharmaceutical Company
1.3.3 Academic Scientific Research Institution
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector CDMO Market Perspective (2020-2031)
2.2 Global Viral Vector CDMO Growth Trends by Region
2.2.1 Global Viral Vector CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Viral Vector CDMO Historic Market Size by Region (2020-2025)
2.2.3 Viral Vector CDMO Forecasted Market Size by Region (2026-2031)
2.3 Viral Vector CDMO Market Dynamics
2.3.1 Viral Vector CDMO Industry Trends
2.3.2 Viral Vector CDMO Market Drivers
2.3.3 Viral Vector CDMO Market Challenges
2.3.4 Viral Vector CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vector CDMO Players by Revenue
3.1.1 Global Top Viral Vector CDMO Players by Revenue (2020-2025)
3.1.2 Global Viral Vector CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Viral Vector CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Viral Vector CDMO Revenue
3.4 Global Viral Vector CDMO Market Concentration Ratio
3.4.1 Global Viral Vector CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector CDMO Revenue in 2024
3.5 Global Key Players of Viral Vector CDMO Head office and Area Served
3.6 Global Key Players of Viral Vector CDMO, Product and Application
3.7 Global Key Players of Viral Vector CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector CDMO Breakdown Data by Type
4.1 Global Viral Vector CDMO Historic Market Size by Type (2020-2025)
4.2 Global Viral Vector CDMO Forecasted Market Size by Type (2026-2031)
5 Viral Vector CDMO Breakdown Data by Application
5.1 Global Viral Vector CDMO Historic Market Size by Application (2020-2025)
5.2 Global Viral Vector CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Viral Vector CDMO Market Size (2020-2031)
6.2 North America Viral Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Viral Vector CDMO Market Size by Country (2020-2025)
6.4 North America Viral Vector CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vector CDMO Market Size (2020-2031)
7.2 Europe Viral Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Viral Vector CDMO Market Size by Country (2020-2025)
7.4 Europe Viral Vector CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vector CDMO Market Size (2020-2031)
8.2 Asia-Pacific Viral Vector CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Viral Vector CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Viral Vector CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vector CDMO Market Size (2020-2031)
9.2 Latin America Viral Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Viral Vector CDMO Market Size by Country (2020-2025)
9.4 Latin America Viral Vector CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vector CDMO Market Size (2020-2031)
10.2 Middle East & Africa Viral Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Viral Vector CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Viral Vector CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Viral Vector CDMO Introduction
11.1.4 Thermo Fisher Scientific Revenue in Viral Vector CDMO Business (2020-2025)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 GenScript ProBio
11.2.1 GenScript ProBio Company Details
11.2.2 GenScript ProBio Business Overview
11.2.3 GenScript ProBio Viral Vector CDMO Introduction
11.2.4 GenScript ProBio Revenue in Viral Vector CDMO Business (2020-2025)
11.2.5 GenScript ProBio Recent Development
11.3 Hillgene
11.3.1 Hillgene Company Details
11.3.2 Hillgene Business Overview
11.3.3 Hillgene Viral Vector CDMO Introduction
11.3.4 Hillgene Revenue in Viral Vector CDMO Business (2020-2025)
11.3.5 Hillgene Recent Development
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Details
11.4.2 Charles River Laboratories Business Overview
11.4.3 Charles River Laboratories Viral Vector CDMO Introduction
11.4.4 Charles River Laboratories Revenue in Viral Vector CDMO Business (2020-2025)
11.4.5 Charles River Laboratories Recent Development
11.5 Ubrigene
11.5.1 Ubrigene Company Details
11.5.2 Ubrigene Business Overview
11.5.3 Ubrigene Viral Vector CDMO Introduction
11.5.4 Ubrigene Revenue in Viral Vector CDMO Business (2020-2025)
11.5.5 Ubrigene Recent Development
11.6 Obio Technology (shanghai)
11.6.1 Obio Technology (shanghai) Company Details
11.6.2 Obio Technology (shanghai) Business Overview
11.6.3 Obio Technology (shanghai) Viral Vector CDMO Introduction
11.6.4 Obio Technology (shanghai) Revenue in Viral Vector CDMO Business (2020-2025)
11.6.5 Obio Technology (shanghai) Recent Development
11.7 Genesail Biotech (Shanghai)
11.7.1 Genesail Biotech (Shanghai) Company Details
11.7.2 Genesail Biotech (Shanghai) Business Overview
11.7.3 Genesail Biotech (Shanghai) Viral Vector CDMO Introduction
11.7.4 Genesail Biotech (Shanghai) Revenue in Viral Vector CDMO Business (2020-2025)
11.7.5 Genesail Biotech (Shanghai) Recent Development
11.8 WuXi ATU
11.8.1 WuXi ATU Company Details
11.8.2 WuXi ATU Business Overview
11.8.3 WuXi ATU Viral Vector CDMO Introduction
11.8.4 WuXi ATU Revenue in Viral Vector CDMO Business (2020-2025)
11.8.5 WuXi ATU Recent Development
11.9 Porton Advanced Solutions
11.9.1 Porton Advanced Solutions Company Details
11.9.2 Porton Advanced Solutions Business Overview
11.9.3 Porton Advanced Solutions Viral Vector CDMO Introduction
11.9.4 Porton Advanced Solutions Revenue in Viral Vector CDMO Business (2020-2025)
11.9.5 Porton Advanced Solutions Recent Development
11.10 Pharmaron
11.10.1 Pharmaron Company Details
11.10.2 Pharmaron Business Overview
11.10.3 Pharmaron Viral Vector CDMO Introduction
11.10.4 Pharmaron Revenue in Viral Vector CDMO Business (2020-2025)
11.10.5 Pharmaron Recent Development
11.11 Asymchem Laboratories (Tianjin)
11.11.1 Asymchem Laboratories (Tianjin) Company Details
11.11.2 Asymchem Laboratories (Tianjin) Business Overview
11.11.3 Asymchem Laboratories (Tianjin) Viral Vector CDMO Introduction
11.11.4 Asymchem Laboratories (Tianjin) Revenue in Viral Vector CDMO Business (2020-2025)
11.11.5 Asymchem Laboratories (Tianjin) Recent Development
11.12 Merck
11.12.1 Merck Company Details
11.12.2 Merck Business Overview
11.12.3 Merck Viral Vector CDMO Introduction
11.12.4 Merck Revenue in Viral Vector CDMO Business (2020-2025)
11.12.5 Merck Recent Development
11.13 VectorBuilder
11.13.1 VectorBuilder Company Details
11.13.2 VectorBuilder Business Overview
11.13.3 VectorBuilder Viral Vector CDMO Introduction
11.13.4 VectorBuilder Revenue in Viral Vector CDMO Business (2020-2025)
11.13.5 VectorBuilder Recent Development
11.14 Yposkesi
11.14.1 Yposkesi Company Details
11.14.2 Yposkesi Business Overview
11.14.3 Yposkesi Viral Vector CDMO Introduction
11.14.4 Yposkesi Revenue in Viral Vector CDMO Business (2020-2025)
11.14.5 Yposkesi Recent Development
11.15 Flash Therapeutics
11.15.1 Flash Therapeutics Company Details
11.15.2 Flash Therapeutics Business Overview
11.15.3 Flash Therapeutics Viral Vector CDMO Introduction
11.15.4 Flash Therapeutics Revenue in Viral Vector CDMO Business (2020-2025)
11.15.5 Flash Therapeutics Recent Development
11.16 VIVEBiotech
11.16.1 VIVEBiotech Company Details
11.16.2 VIVEBiotech Business Overview
11.16.3 VIVEBiotech Viral Vector CDMO Introduction
11.16.4 VIVEBiotech Revenue in Viral Vector CDMO Business (2020-2025)
11.16.5 VIVEBiotech Recent Development
11.17 Miltenyi Bioindustry
11.17.1 Miltenyi Bioindustry Company Details
11.17.2 Miltenyi Bioindustry Business Overview
11.17.3 Miltenyi Bioindustry Viral Vector CDMO Introduction
11.17.4 Miltenyi Bioindustry Revenue in Viral Vector CDMO Business (2020-2025)
11.17.5 Miltenyi Bioindustry Recent Development
11.18 Genezen
11.18.1 Genezen Company Details
11.18.2 Genezen Business Overview
11.18.3 Genezen Viral Vector CDMO Introduction
11.18.4 Genezen Revenue in Viral Vector CDMO Business (2020-2025)
11.18.5 Genezen Recent Development
11.19 Miltenyi Biotec
11.19.1 Miltenyi Biotec Company Details
11.19.2 Miltenyi Biotec Business Overview
11.19.3 Miltenyi Biotec Viral Vector CDMO Introduction
11.19.4 Miltenyi Biotec Revenue in Viral Vector CDMO Business (2020-2025)
11.19.5 Miltenyi Biotec Recent Development
11.20 Exthera
11.20.1 Exthera Company Details
11.20.2 Exthera Business Overview
11.20.3 Exthera Viral Vector CDMO Introduction
11.20.4 Exthera Revenue in Viral Vector CDMO Business (2020-2025)
11.20.5 Exthera Recent Development
11.21 Catalent
11.21.1 Catalent Company Details
11.21.2 Catalent Business Overview
11.21.3 Catalent Viral Vector CDMO Introduction
11.21.4 Catalent Revenue in Viral Vector CDMO Business (2020-2025)
11.21.5 Catalent Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Viral Vector CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of IIT Grade
Table 3. Key Players of IND Grade
Table 4. Key Players of Clinical Trial Grade
Table 5. Key Players of Commercial Production Grade
Table 6. Global Viral Vector CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Viral Vector CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Viral Vector CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Viral Vector CDMO Market Share by Region (2020-2025)
Table 10. Global Viral Vector CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Viral Vector CDMO Market Share by Region (2026-2031)
Table 12. Viral Vector CDMO Market Trends
Table 13. Viral Vector CDMO Market Drivers
Table 14. Viral Vector CDMO Market Challenges
Table 15. Viral Vector CDMO Market Restraints
Table 16. Global Viral Vector CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Viral Vector CDMO Market Share by Players (2020-2025)
Table 18. Global Top Viral Vector CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector CDMO as of 2024)
Table 19. Ranking of Global Top Viral Vector CDMO Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Viral Vector CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Viral Vector CDMO, Headquarters and Area Served
Table 22. Global Key Players of Viral Vector CDMO, Product and Application
Table 23. Global Key Players of Viral Vector CDMO, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Viral Vector CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Viral Vector CDMO Revenue Market Share by Type (2020-2025)
Table 27. Global Viral Vector CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Viral Vector CDMO Revenue Market Share by Type (2026-2031)
Table 29. Global Viral Vector CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Viral Vector CDMO Revenue Market Share by Application (2020-2025)
Table 31. Global Viral Vector CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Viral Vector CDMO Revenue Market Share by Application (2026-2031)
Table 33. North America Viral Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Viral Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Viral Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Viral Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Viral Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Viral Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Viral Vector CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Viral Vector CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Viral Vector CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Viral Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Viral Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Viral Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Viral Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Viral Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Viral Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 48. Thermo Fisher Scientific Company Details
Table 49. Thermo Fisher Scientific Business Overview
Table 50. Thermo Fisher Scientific Viral Vector CDMO Product
Table 51. Thermo Fisher Scientific Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 52. Thermo Fisher Scientific Recent Development
Table 53. GenScript ProBio Company Details
Table 54. GenScript ProBio Business Overview
Table 55. GenScript ProBio Viral Vector CDMO Product
Table 56. GenScript ProBio Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 57. GenScript ProBio Recent Development
Table 58. Hillgene Company Details
Table 59. Hillgene Business Overview
Table 60. Hillgene Viral Vector CDMO Product
Table 61. Hillgene Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 62. Hillgene Recent Development
Table 63. Charles River Laboratories Company Details
Table 64. Charles River Laboratories Business Overview
Table 65. Charles River Laboratories Viral Vector CDMO Product
Table 66. Charles River Laboratories Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 67. Charles River Laboratories Recent Development
Table 68. Ubrigene Company Details
Table 69. Ubrigene Business Overview
Table 70. Ubrigene Viral Vector CDMO Product
Table 71. Ubrigene Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 72. Ubrigene Recent Development
Table 73. Obio Technology (shanghai) Company Details
Table 74. Obio Technology (shanghai) Business Overview
Table 75. Obio Technology (shanghai) Viral Vector CDMO Product
Table 76. Obio Technology (shanghai) Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 77. Obio Technology (shanghai) Recent Development
Table 78. Genesail Biotech (Shanghai) Company Details
Table 79. Genesail Biotech (Shanghai) Business Overview
Table 80. Genesail Biotech (Shanghai) Viral Vector CDMO Product
Table 81. Genesail Biotech (Shanghai) Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 82. Genesail Biotech (Shanghai) Recent Development
Table 83. WuXi ATU Company Details
Table 84. WuXi ATU Business Overview
Table 85. WuXi ATU Viral Vector CDMO Product
Table 86. WuXi ATU Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 87. WuXi ATU Recent Development
Table 88. Porton Advanced Solutions Company Details
Table 89. Porton Advanced Solutions Business Overview
Table 90. Porton Advanced Solutions Viral Vector CDMO Product
Table 91. Porton Advanced Solutions Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 92. Porton Advanced Solutions Recent Development
Table 93. Pharmaron Company Details
Table 94. Pharmaron Business Overview
Table 95. Pharmaron Viral Vector CDMO Product
Table 96. Pharmaron Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 97. Pharmaron Recent Development
Table 98. Asymchem Laboratories (Tianjin) Company Details
Table 99. Asymchem Laboratories (Tianjin) Business Overview
Table 100. Asymchem Laboratories (Tianjin) Viral Vector CDMO Product
Table 101. Asymchem Laboratories (Tianjin) Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 102. Asymchem Laboratories (Tianjin) Recent Development
Table 103. Merck Company Details
Table 104. Merck Business Overview
Table 105. Merck Viral Vector CDMO Product
Table 106. Merck Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 107. Merck Recent Development
Table 108. VectorBuilder Company Details
Table 109. VectorBuilder Business Overview
Table 110. VectorBuilder Viral Vector CDMO Product
Table 111. VectorBuilder Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 112. VectorBuilder Recent Development
Table 113. Yposkesi Company Details
Table 114. Yposkesi Business Overview
Table 115. Yposkesi Viral Vector CDMO Product
Table 116. Yposkesi Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 117. Yposkesi Recent Development
Table 118. Flash Therapeutics Company Details
Table 119. Flash Therapeutics Business Overview
Table 120. Flash Therapeutics Viral Vector CDMO Product
Table 121. Flash Therapeutics Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 122. Flash Therapeutics Recent Development
Table 123. VIVEBiotech Company Details
Table 124. VIVEBiotech Business Overview
Table 125. VIVEBiotech Viral Vector CDMO Product
Table 126. VIVEBiotech Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 127. VIVEBiotech Recent Development
Table 128. Miltenyi Bioindustry Company Details
Table 129. Miltenyi Bioindustry Business Overview
Table 130. Miltenyi Bioindustry Viral Vector CDMO Product
Table 131. Miltenyi Bioindustry Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 132. Miltenyi Bioindustry Recent Development
Table 133. Genezen Company Details
Table 134. Genezen Business Overview
Table 135. Genezen Viral Vector CDMO Product
Table 136. Genezen Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 137. Genezen Recent Development
Table 138. Miltenyi Biotec Company Details
Table 139. Miltenyi Biotec Business Overview
Table 140. Miltenyi Biotec Viral Vector CDMO Product
Table 141. Miltenyi Biotec Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 142. Miltenyi Biotec Recent Development
Table 143. Exthera Company Details
Table 144. Exthera Business Overview
Table 145. Exthera Viral Vector CDMO Product
Table 146. Exthera Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 147. Exthera Recent Development
Table 148. Catalent Company Details
Table 149. Catalent Business Overview
Table 150. Catalent Viral Vector CDMO Product
Table 151. Catalent Revenue in Viral Vector CDMO Business (2020-2025) & (US$ Million)
Table 152. Catalent Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report


List of Figures
Figure 1. Viral Vector CDMO Picture
Figure 2. Global Viral Vector CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Viral Vector CDMO Market Share by Type: 2024 VS 2031
Figure 4. IIT Grade Features
Figure 5. IND Grade Features
Figure 6. Clinical Trial Grade Features
Figure 7. Commercial Production Grade Features
Figure 8. Global Viral Vector CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Viral Vector CDMO Market Share by Application: 2024 VS 2031
Figure 10. Biopharmaceutical Company Case Studies
Figure 11. Academic Scientific Research Institution Case Studies
Figure 12. Viral Vector CDMO Report Years Considered
Figure 13. Global Viral Vector CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Viral Vector CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Viral Vector CDMO Market Share by Region: 2024 VS 2031
Figure 16. Global Viral Vector CDMO Market Share by Players in 2024
Figure 17. Global Top Viral Vector CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector CDMO as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Viral Vector CDMO Revenue in 2024
Figure 19. North America Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Viral Vector CDMO Market Share by Country (2020-2031)
Figure 21. United States Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Viral Vector CDMO Market Share by Country (2020-2031)
Figure 25. Germany Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Viral Vector CDMO Market Share by Region (2020-2031)
Figure 33. China Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Viral Vector CDMO Market Share by Country (2020-2031)
Figure 41. Mexico Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Viral Vector CDMO Market Share by Country (2020-2031)
Figure 45. Turkey Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Viral Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 49. GenScript ProBio Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 50. Hillgene Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 51. Charles River Laboratories Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 52. Ubrigene Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 53. Obio Technology (shanghai) Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 54. Genesail Biotech (Shanghai) Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 55. WuXi ATU Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 56. Porton Advanced Solutions Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 57. Pharmaron Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 58. Asymchem Laboratories (Tianjin) Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 59. Merck Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 60. VectorBuilder Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 61. Yposkesi Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 62. Flash Therapeutics Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 63. VIVEBiotech Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 64. Miltenyi Bioindustry Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 65. Genezen Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 66. Miltenyi Biotec Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 67. Exthera Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 68. Catalent Revenue Growth Rate in Viral Vector CDMO Business (2020-2025)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies